A major Wall Street endorsement from multiple analysts recently sent shares of Seagate Technology (NASDAQ: STX) up over 7% in a single session, pushing the stock to a new 52-week high. While any double-digit price target increase is notable, the market’s decisive reaction points to a much .... |
Good MorningWall Street extended its winning streak as major indexes climbed to new highs on broad strength in technology shares. The S&P 500 rose 0.5%, the Dow Jones Industrial Average gained 0.3% and the Nasdaq Composite jumped 0.9%, all setting fresh records. Small-cap stocks also rallied, pushing the Russell 2000 above its 2021 peak. Driving much of today’s surge was a partnership announcement between NVIDIA and Intel, sending NVIDIA higher after it revealed a $5 billion equity investment in its longtime rival as the two plan to co-develop data-center and PC products. International futures reflected the upbeat mood, with Japan’s Nikkei 225 futures trading near multi-year highs.
Fixed-income markets registered notable moves ahead of the Federal Reserve’s anticipated first rate cut, with long-term Treasury yields slipping and mortgage rates dipping to their lowest level since early October. The average 30-year fixed mortgage rate fell to 6.26%, down from 6.35% last week, according to Freddie Mac. Overseas, the Bank of England held its benchmark rate at 4% amid lingering inflation concerns, while commodities saw mixed action: crude oil futures edged lower below $64 a barrel and gold prices retreated as the dollar strengthened slightly.
In corporate news, Uber Eats announced a partnership with drone operator Flytrex to begin U.S. deliveries by year-end, underscoring the growing role of logistics technology in food services. Automakers also made headlines as Toyota and Hyundai issued recalls on more than 1.1 million vehicles over seat-belt and instrument-panel issues, a development that could ripple through auto-supplier stocks. Meanwhile, U.S. homeowners and buyers of electric vehicles and heat pumps are racing to claim expiring federal tax credits before year’s end, setting up a late-season boost in clean-energy and home-improvement demand. Featured: 120 days remain before new defense mineral rules take effect (Ad) 
| Technology | |
A major Wall Street endorsement from multiple analysts recently sent shares of Seagate Technology (NASDAQ: STX) up over 7% in a single session, pushing the stock to a new 52-week high. While any double-digit price target increase is notable, the market’s decisive reaction points to a much ... Read the Full Story |
| From Our Partners | | Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldrush, and Cortez Hills, deposits that could hold up to 60 million ounces of gold.
One overlooked explorer controls 142 claims bordering Fourmile and sitting less than a mile from Goldrush. New geological modeling aims to reveal what's beneath this largely untested ground, while a planned 5% royalty spin-off could give shareholders a separate stake in the project. | | Read the full report before the next catalyst hits |
| Technology | |
Artificial intelligence (AI) is an all-consuming investment thesis that will last for years, if not decades. For many investors, that means investing in some of the year’s hottest stocks, such as NVIDIA (NASDAQ: NVDA) or Palantir (NASDAQ: PLTR). However, many investors are attracted to compa... Read the Full Story |
| Technology | |
Shares of D-Wave Quantum Inc. (NYSE: QBTS) rallied by an impressive 94% year-to-date, but a closer look reveals that the firm is in danger of losing momentum. When looking at the 12-month trailing return of an astronomical 1,800%, the company's performance over 2025 so far is not quite as notewort... Read the Full Story |
| From Our Partners | | A new tool called Oracle tracks insider bets hidden in the predictions market, flagging which stocks and options could be affected.
During beta testing, Oracle identified notable short-term moves including USO up 39% in four days, PLTR up 43% in a day, and WEN up 67% in two days, all through a regular brokerage account.
See how Oracle spots these hidden insider bets before they make headlines. | | Get free access to Oracle and see the data now |
| Healthcare | |
Eli Lilly and Company (NYSE: LLY) has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks over the past 12 months. The company is the leader in the GLP-1 market, which is transforming the management of type 2 diabetes and the obesity market.
LLY stock is up 10... Read the Full Story |
| Markets | |
The FOMC cut interest rates, but the media response indicated that the cuts were less than expected. However, the headlines focused on next year’s tepid outlook for only 25 basis points of cuts are missing the forest for all the trees. While next year’s outlook is tepid, the forecast f... Read the Full Story |
| From Our Partners | | A 20-minute read could change how you approach your next options trade. Chris Pulver is giving away his guide, Right About The Market, Wrong About The Money, free of charge.
Built from two decades of trading experience, the guide tackles a common problem: losing a trade even when your market call was correct.
No cost, no catch, just a packed resource for options traders who want a sharper edge. | | Click here to get your free copy of the guide |
| Industrials | |
Bloom Energy (NYSE: BE) received two price target upgrades from two major Wall Street firms in two weeks, citing very similar rationale. This served as a launch signal, igniting two additional booster rockets on a stock already accelerating toward triple-digit territory.
BE stock recently jumpe... Read the Full Story |
| Technology | |
After the start of a rally in August that captured significant investor attention, shares of Intel Corporation (NASDAQ: INTC) have entered a period of consolidation, establishing a new and higher base in the $25 to $26 range. This sideways trading, however, follows a period of positive fundament... Read the Full Story |
| Technology | |
During the first half of September, tech giant Apple (NASDAQ: AAPL) made multiple key product and software announcements. Of course, the most talked about is its latest iPhone lineup on Sept. 9, followed by a deeper reveal of its Apple Intelligence features on Sept. 15.
Over the past several ye... Read the Full Story |
| Technology | |
Oracle (NYSE: ORCL) will soon reach a trillion-dollar valuation, driven by the impact of AI on business operations.
Once a bulky, cumbersome shackle, data has become a treasure trove for businesses, and Oracle is leading the charge to unlock it.
Its fiscal Q1 results prove its leadership posit... Read the Full Story |
| Consumer Staples | |
General Mills' (NYSE: GIS) stock sell-off, warranted or not, has aligned its market with long-term trends and presents a generational opportunity for investors. At mid-September levels, the stock is trading at historically low valuations and yielding nearly 5%, a fascinating figure given the out... Read the Full Story |
| Friday's Early Bird Stock Of The Day Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. | Should I Buy Gilead Sciences Stock? GILD Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Saturday, August 29, 2026 at 6:10 PM.
Gilead Sciences Bull Case -
The recent approval of Bixlenvo, a once-daily single-tablet regimen for HIV treatment, positions Gilead Sciences, Inc. to expand its market share in the antiviral sector, potentially leading to increased revenue.
-
Gilead Sciences, Inc. reported a quarterly revenue of $7.80 billion, surpassing analyst expectations, indicating strong financial performance and growth potential.
-
The current stock price is around $134, which may present a buying opportunity for investors looking to enter at a favorable valuation.
-
With a market capitalization of approximately $180.64 billion, Gilead Sciences, Inc. is a significant player in the biopharmaceutical industry, providing stability and credibility to investors.
-
The company has a diverse product portfolio that includes therapies for HIV, oncology, and inflammatory diseases, reducing reliance on any single product line and enhancing long-term growth prospects.
Gilead Sciences Bear Case -
Gilead Sciences, Inc. has a negative return on equity, indicating that the company is not generating profit from its equity, which could be a red flag for potential investors.
-
The company reported a negative net margin, suggesting that it is currently facing challenges in profitability, which may affect future earnings.
-
Analysts predict that Gilead Sciences, Inc. will post negative earnings per share for the current year, which could signal ongoing financial difficulties.
-
The dividend payout ratio is significantly negative, indicating that the company is paying out more in dividends than it is earning, which is unsustainable in the long term.
-
Despite recent approvals, the competitive landscape in the biopharmaceutical sector is intense, and Gilead Sciences, Inc. may face challenges in maintaining its market position against emerging therapies.
| | View Today's Stock Pick |
|
| |
|
|
